Walgreens kicks off nationwide safe medication-disposal program
DEERFIELD, Ill. Walgreens has teamed up with Sharps Compliance to launch the drug store chain’s first-ever safe medication-disposal program.
Walgreens said the program is designed to protect public safety, as well as ease the concern of parents that fear children and teens can access unused medications at home. The company has kicked off this program with the help of Sharps Compliance, a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications, which estimated that more than 200 million lbs. of unused dispensed medications are disposed of improperly each year.
How it works: For $2.99, customers can purchase a specially designed envelope — postage cost included — available at any Walgreens pharmacy counter that allows them to place, seal and mail prescription or over-the-counter medications they no longer use for safe, eco-friendly disposal. Controlled substances are excluded from the program, Walgreens said.
“In thousands of communities, Walgreens serves as the most accessible source of everyday health information,” said Walgreens VP pharmacy operations Richard Ashworth. “That makes us a natural choice for guidance on anything involving medications, including proper disposal. Through this program, we can do our part to keep expired or unused medications out of waterways and out of the hands of those who could be accidentally harmed.”
FTC looks to debunk health benefit claims made by POM Wonderful in suit
WASHINGTON The Federal Trade Commission has sued the maker of a pomegranate juice that touts health benefit claims.
The FTC announced that it was suing POM Wonderful for its "deceptive advertising" on Monday. Federal regulators alleged that ads that ran in such publications as the New York Times, as well as Parade, Fitness and Prevention magazines, violated federal law by making deceptive disease prevention and treatment claims, including "clinical studies prove that POM Juice and POMx prevent, reduce the risk of and treat [heart disease, prostate cancer and erectile dysfunction]." The FTC complaint said that the claims are false because the company either:
- Conducted scientific studies that did not show heart disease benefit from use of its products;
- The study POM Wonderful relied on was neither “blinded” nor controlled (to merit prostate cancer claims); or
- The study on which the company relied (for erectile dysfunction claims) did not show that POM Juice was any more effective than a placebo.
“Any consumer who sees POM Wonderful products as a silver bullet against disease has been misled,” said David Vladeck, director of the FTC’s Bureau of Consumer Protection. “When a company touts scientific research in its advertising, the research must squarely support the claims made. Contrary to POM Wonderful’s advertising, the available scientific information does not prove that POM Juice or POMx effectively treats or prevents these illnesses.”
The FTC issues an administrative complaint when it has reason to believe that the law has been or is being violated, and it appears to the commission that a proceeding is in the public interest, the government agency noted.
Oncologists favor biosimilar adoption, Decision Resources finds
BURLINGTON, Mass. While biosimilars promise to provide therapies for a wide range of diseases, their biggest fans may come from cancer specialists, according to a new report.
Healthcare market research firm Decision Resources found in a report that oncologists would be the most aggressive in adopting biosimilars compared with other specialists because of their lower clinical trial requirements. According to research, oncologists in the United States will adopt biosimilars faster than their European counterparts because they will require fewer and shorter phase-3 clinical trials before they feel comfortable prescribing them.
The firm expected biosimilars of granulocyte colony-stimulating factor, as well as biosimilars of monoclonal antibody therapies used to treat cancer, to reduce brand sales by more than $7 billion in 2019 in the United States, Japan, the United Kingdom, France, Germany, Italy and Spain, which Decision Resources collectively refers to as the “EU5.”
“Because of patent expiries and more-established regulatory pathways for approving biosimilars in Europe, most biosimilar [monoclonal antibodies] will launch in the EU5 before the United States,” Decision Resources analyst Cindy Fung said. “As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents.”